NeoGenomics, Inc. · NASDAQ:NEO

NeoGenomics — ASH 2020

11 slides from NeoGenomics's conference presentation, 2020

  1. Slide 1: Accessing Genomic Alterations in CLL using an NGS-based Comprehensive Genomic Profiling Assay

    Slide 1: Accessing Genomic Alterations in CLL using an NGS-based Comprehensive Genomic Profiling Assay

    Accessing Genomic Alternations in Chronic Lymphocytic Leukemia using an NGS-based Comprehensive Genomic Profiling Assay( #1303) Segun C. Jung, PhD segun.jung@neogenomics.com

  2. Slide 2: Background

    Slide 2: Background

    2 Background • For detecting copy number abnormalities (CNAs), fluorescence in situ hybridization (FISH) and conventional cytogenetics (CC) are the gold standard • NGS is emerging as a comprehensive assay that can detect CNAs as well as SNVs, INDELs and loss of heterozygosity (CN-LOH) at much higher

  3. Slide 3: A comprehensive genomic profiling approach to interrogate hematologic malignancies

    Slide 3: A comprehensive genomic profiling approach to interrogate hematologic malignancies

    A comprehensive genomic profiling (CGP) approach to interrogate hematologic malignancies using a novel multimodal next generation sequencing assay • 297 genes (DNA) • 213 genes (RNA) SNV, INDEL, CNV ABL1 ABL2 ARID1A ARID1B AKT1 ARID2 AKT2 ASXL1 AKT3 ASXL2 ALK ATG2B ANKRD26 APC ATM ATP2B ARAF ATRX AR

  4. Slide 4: Multimodal NGS workflow of LDT assay

    Slide 4: Multimodal NGS workflow of LDT assay

    Multimodal NGS workflow of LDT assay DNA+RNA NGS Run Data SNV, INDEL Library Prep (Nova 6000) Analysis CNV DNA Pipeline Annotation Alignment UMI dedup Alignment Variant calling Base Calls FASTQ Interpretation (*.bam) (*.fastq) (*.bam) (*.vcf) (BCL) Reporting QC QC Panel of CNV Normal caller2 Ensembl

  5. Slide 5: CNA Detection

    Slide 5: CNA Detection

    CNA Detection 5 • CNV measured by the ratio of tumor to normal DNA abundance • Certain CNVs not only prognostic, but also predictive biomarker • Loss of heterozygosity (LOH) is due to allelic imbalance (i.e. heterozygous germline to homozygous somatic mutation Aouiche et al. Quantitative Biology. 6:

  6. Slide 6: CNV detection in Chronic Lymphocytic Leukemia (CLL)

    Slide 6: CNV detection in Chronic Lymphocytic Leukemia (CLL)

    CNV detection in Chronic Lymphocytic Leukemia (CLL) Established for prognosis Chromosome Abnormality Prevalence(%) Genes Prognostic significance 11q22.3 loss 10-20 ATM, BIRC3, Unfavorable MRE11, H2AFX 12 gain 10-20 Unknown Intermediate 13q14 loss 50-60 DLEU1, DLEU2 Favorable 17p13.1 loss 5-15 TP53 U

  7. Slide 7: Frequency of copy number gains and losses in CLL (n=236)

    Slide 7: Frequency of copy number gains and losses in CLL (n=236)

    Frequency of copy number gains and losses in CLL (n=236) CN gain KRAS_p.G13D KRAS_p.G12D CN loss KMT2D_p.M3398L Sample count MEF2B_p.L275Q ERBB2_p.Y908F IKZF3_p.L162R BLM_p.N515Mfs*16 Sample count TP53_p.H179R KMT2C_p.E2798Gfs*11 NOTCH1_p.P2514Rfs*4 Chromosome

  8. Slide 8: CNA detection in Chronic Lymphocytic Leukemia (CLL)

    Slide 8: CNA detection in Chronic Lymphocytic Leukemia (CLL)

    CNA detection in Chronic Lymphocytic Leukemia (CLL) MYB ATM TP53 chromosomes 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 sample-1 gain sample-2 sample-3 loss sample-4 sample-5 sample-6 Cytogenetic only sample-7 sample-8 NGS only sample-9 sample-10 sample-11 Suspected for prognosis sampl

  9. Slide 9: 2p gain in CLL

    Slide 9: 2p gain in CLL

    2p gain in CLL case1 case2 case3 gain gain gain Chr Pos ID REF ALT Gene Chr Pos ID REF ALT Gene DNMT3 2 25994416 rs372407443 A G ASXL2 2 25469913 rs2276599 C T A EPCA Chr Pos ID REF ALT Gene 2 47601106 rs1126497 T C M 2 25994412 rs71399322 A AG ASXL2 2 25994416 rs372407443 A G ASXL2 2 29446202 rs462

  10. Slide 10: Conclusions

    Slide 10: Conclusions

    Conclusions • NGS and CC results agree with 91% accuracy • NGS and FISH results agree with 77% accuracy • CN-LOH was mostly detected on chromosomes 13q, 17p and 22q • Several pathogenic and VUS mutations were detected that may correlate with the CNAs

  11. Slide 11: Disclosure

    Slide 11: Disclosure

    DISCLOSURE I have relevant financial relationships with the materials and results in this presentation. • Financial • Principal Scientist of Research and Development at NeoGenomics Laboratories • Shareholder of Neogenomics Laboratories

Source: Internet Archive copy of neogenomics.com

More decks from NeoGenomics, Inc.

All 44 NeoGenomics decks